$ACHV
ACHIEVE LIFE SCIENCES, INC.

2014 Q3 Form 10-Q Financial Statement

#000119312514300691 Filed on August 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q3 2014 Q2 2013 Q2
Revenue $4.800M $4.930M $6.340M
YoY Change -51.32% -22.24% 160.91%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.460M $2.680M $2.470M
YoY Change -0.4% 8.5% 20.49%
% of Gross Profit
Research & Development $9.586M $9.883M $13.26M
YoY Change -46.76% -25.48% 109.66%
% of Gross Profit
Depreciation & Amortization $60.00K $50.00K $60.00K
YoY Change 0.0% -16.67% 200.0%
% of Gross Profit
Operating Expenses $12.05M $9.883M $13.26M
YoY Change -33.1% -25.48% 109.66%
Operating Profit
YoY Change
Interest Expense $0.00 $0.00 $40.00K
YoY Change -100.0% -100.0% -55.56%
% of Operating Profit
Other Income/Expense, Net $2.335M $615.0K $976.0K
YoY Change 316.22% -36.99% -43.55%
Pretax Income -$4.910M -$7.020M -$8.420M
YoY Change -51.14% -16.63% 99.53%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.907M -$7.015M -$8.420M
YoY Change -51.19% -16.69% 99.76%
Net Earnings / Revenue -102.23% -142.29% -132.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$491.0M -$702.0M -$842.0M
COMMON SHARES
Basic Shares Outstanding 21.14M shares 14.75M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q3 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.00M $40.60M $57.00M
YoY Change 15.38% -28.77% -41.6%
Cash & Equivalents $48.95M $40.61M $18.75M
Short-Term Investments $5.100M $0.00 $38.20M
Other Short-Term Assets $2.500M $2.300M $3.500M
YoY Change -7.41% -34.29% -44.44%
Inventory
Prepaid Expenses
Receivables $4.827M $4.951M $6.400M
Other Receivables $0.00 $0.00 $300.0K
Total Short-Term Assets $61.32M $47.85M $67.30M
YoY Change 2.69% -28.9% -35.84%
LONG-TERM ASSETS
Property, Plant & Equipment $312.0K $354.0K $500.0K
YoY Change -29.57% -29.2% 150.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $773.0K $1.274M $1.500M
YoY Change -34.21% -15.07% -48.28%
Total Long-Term Assets $1.336M $1.879M $2.000M
YoY Change -30.85% -6.05% -35.48%
TOTAL ASSETS
Total Short-Term Assets $61.32M $47.85M $67.30M
Total Long-Term Assets $1.336M $1.879M $2.000M
Total Assets $62.65M $49.73M $69.30M
YoY Change 1.64% -28.24% -35.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.562M $1.341M $100.0K
YoY Change 3905.13% 1241.0% -96.55%
Accrued Expenses $13.17M $13.25M $10.40M
YoY Change 16.17% 27.39%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.100M $1.100M $1.100M
YoY Change 0.0% 0.0% -21.43%
Total Short-Term Liabilities $20.93M $20.17M $12.70M
YoY Change 45.65% 58.83% -53.65%
LONG-TERM LIABILITIES
Long-Term Debt $2.900M $3.100M $3.900M
YoY Change -21.62% -20.51% -33.9%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $2.900M $3.100M $3.900M
YoY Change -21.62% -20.51% -33.9%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.93M $20.17M $12.70M
Total Long-Term Liabilities $2.900M $3.100M $3.900M
Total Liabilities $23.80M $23.27M $16.60M
YoY Change 31.52% 40.16% -50.15%
SHAREHOLDERS EQUITY
Retained Earnings -$154.3M -$149.3M
YoY Change 21.47%
Common Stock $190.5M $173.2M
YoY Change 13.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.85M $26.47M $52.70M
YoY Change
Total Liabilities & Shareholders Equity $62.65M $49.73M $69.30M
YoY Change 1.64% -28.24% -35.83%

Cashflow Statement

Concept 2014 Q3 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$4.907M -$7.015M -$8.420M
YoY Change -51.19% -16.69% 99.76%
Depreciation, Depletion And Amortization $60.00K $50.00K $60.00K
YoY Change 0.0% -16.67% 200.0%
Cash From Operating Activities -$5.760M -$2.910M -$7.470M
YoY Change -43.7% -61.04% -45.39%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$60.00K -$120.0K
YoY Change -50.0% 33.33%
Acquisitions
YoY Change
Other Investing Activities -$5.060M $8.920M $7.720M
YoY Change -214.74% 15.54% -126.31%
Cash From Investing Activities -$5.070M $8.860M $7.600M
YoY Change -214.97% 16.58% -125.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.17M 6.030M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.760M -2.910M -7.470M
Cash From Investing Activities -5.070M 8.860M 7.600M
Cash From Financing Activities 19.17M 6.030M 0.000
Net Change In Cash 8.340M 11.98M 130.0K
YoY Change -243.3% 9115.38% -100.3%
FREE CASH FLOW
Cash From Operating Activities -$5.760M -$2.910M -$7.470M
Capital Expenditures -$10.00K -$60.00K -$120.0K
Free Cash Flow -$5.750M -$2.850M -$7.350M
YoY Change -43.79% -61.22% -45.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21137038 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18749000
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15577172 shares
CY2014Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1587301 shares
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15577172 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.24
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1258984 shares
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13249000
CY2014Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1106000
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
78000
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
129000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1341000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
20171000
CY2014Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
300000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2641000
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
981000
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
320000
CY2014Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3096000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
26465000
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
173149000
CY2014Q2 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2014Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
320000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-149340000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
15000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49732000
CY2014Q2 us-gaap Liabilities
Liabilities
23267000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
51000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
47853000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
251000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1274000
CY2014Q2 us-gaap Assets
Assets
49732000
CY2014Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
40865000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40614000
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4951000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2288000
CY2014Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0
CY2014Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2014Q2 us-gaap Cash
Cash
18244000
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3700000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
354000
CY2014Q2 ogxi Indemnification Expense
IndemnificationExpense
0
CY2014Q2 ogxi Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
0
CY2014Q2 ogxi Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
0
CY2014Q2 ogxi Common Stock Sales Agreement Net Amount
CommonStockSalesAgreementNetAmount
22000000
CY2014Q2 ogxi Advanced Proceeds From Issuance Of Warrants
AdvancedProceedsFromIssuanceOfWarrants
3174000
CY2014Q2 ogxi Advance Received For Issuing Warrants
AdvanceReceivedForIssuingWarrants
3174000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18075000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14707886 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14707886 shares
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1092000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
139000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14934000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2643000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1705000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
214000
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3544000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
37211000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168242000
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
214000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133689000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55689000
CY2013Q4 us-gaap Liabilities
Liabilities
18478000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.39
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1007491 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11784000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
53867000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
314000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1111000
CY2013Q4 us-gaap Assets
Assets
55689000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14593000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
24629000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8657000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5770000
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
218000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
397000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0116 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8717 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14667244 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18158000
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
20004 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3475 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3000000 shares
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-140000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15138000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
30065000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
132000
us-gaap Investment Income Interest
InvestmentIncomeInterest
91000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-27000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5725000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2558000
us-gaap Net Income Loss
NetIncomeLoss
-15117000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-21000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-21000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2335000
us-gaap Costs And Expenses
CostsAndExpenses
29091000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-404000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4973000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10000
us-gaap Share Based Compensation
ShareBasedCompensation
1603000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
674000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
18840000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5093000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24118000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
49130000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-331000
us-gaap Depreciation
Depreciation
100000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1199000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-18000
ogxi Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
ogxi Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
10000
ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
11416000
dei Trading Symbol
TradingSymbol
OGXI
dei Entity Registrant Name
EntityRegistrantName
ONCOGENEX PHARMACEUTICALS, INC.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0000949858
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0181 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
18.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
12169 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8161 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.92
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14855338 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.07
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4604000
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
49348 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
285097 shares
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15653000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
215000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Investment Income Interest
InvestmentIncomeInterest
16000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-218000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3706000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-92000
us-gaap Net Income Loss
NetIncomeLoss
-15651000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11435 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3700000 shares
us-gaap Depreciation
Depreciation
110000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1202000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-2000
ogxi Class Of Warrant Or Right Exercise Price Of Warrant Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantOrRights
20
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3319000
ogxi Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-63000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
106000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
106000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
2860000
us-gaap Costs And Expenses
CostsAndExpenses
32219000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-724000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5433000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
6064000
us-gaap Share Based Compensation
ShareBasedCompensation
2016000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26021000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
24563000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1465000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26786000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
24845000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-383000
ogxi Expiration Of Non Cancellable Operating Lease Agreement
ExpirationOfNonCancellableOperatingLeaseAgreement
2017
ogxi Maximum Maturity Period Of Short Term Investments
MaximumMaturityPeriodOfShortTermInvestments
P1Y
ogxi Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
51000
ogxi Maximum Maturity Period Of Collateralized Securities
MaximumMaturityPeriodOfCollateralizedSecurities
P1Y
ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
16660000
ogxi Expiration Of Operating Lease Agreement
ExpirationOfOperatingLeaseAgreement
2015-09
ogxi Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
ogxi Class Of Warrant Or Right Expiration Year And Month
ClassOfWarrantOrRightExpirationYearAndMonth
2015-10
ogxi Proceeds In Advance For Issuing Warrants
ProceedsInAdvanceForIssuingWarrants
3174000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14673771 shares
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3000000 shares
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8435000
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
36000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
39000
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
976000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-8420000
CY2013Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-15000
CY2013Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-901000
CY2013Q2 us-gaap Costs And Expenses
CostsAndExpenses
15736000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2473000
CY2013Q2 us-gaap Share Based Compensation
ShareBasedCompensation
855000
CY2013Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13263000
CY2013Q2 ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
6340000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14987706 shares
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3700000 shares
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7016000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
615000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-7015000
CY2014Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2014Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-615000
CY2014Q2 us-gaap Costs And Expenses
CostsAndExpenses
12559000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2676000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1016000
CY2014Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9883000
CY2014Q2 ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
4929000

Files In Submission

Name View Source Status
0001193125-14-300691-index-headers.html Edgar Link pending
0001193125-14-300691-index.html Edgar Link pending
0001193125-14-300691.txt Edgar Link pending
0001193125-14-300691-xbrl.zip Edgar Link pending
d728625d10q.htm Edgar Link pending
d728625dex311.htm Edgar Link pending
d728625dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ogxi-20140630.xml Edgar Link completed
ogxi-20140630.xsd Edgar Link pending
ogxi-20140630_cal.xml Edgar Link unprocessable
ogxi-20140630_def.xml Edgar Link unprocessable
ogxi-20140630_lab.xml Edgar Link unprocessable
ogxi-20140630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending